Skip to main content
. 2021 Jan 27;10:610681. doi: 10.3389/fonc.2020.610681

Figure 3.

Figure 3

Kaplan–Meier survival analysis of overall survival and progression-free survival according to albumin at diagnosis and end-of treatment in the validation cohort. Overall survival (A) and progression-free survival (B) according to albumin at diagnosis in DLBCL patients. Overall survival (C) and progression-free survival (D) according to albumin at end of treatment in DLBCL patients with low serum albumin at diagnosis.